AtriCure ATRC Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue from Contract with Customer, Excluding Assessed Tax by Product | ||||||
| Appendage management | $228.42M+17.8% | $220.18M+18.6% | $212.91M+19.2% | $203.29M+18.6% | $193.88M+17.3% | |
| Minimally invasive ablation | $37.65M-24.5% | $39.85M-26.0% | $43.01M-22.3% | $46.52M-15.5% | $49.9M-7.9% | |
| Open ablation | $191.18M+17.0% | $184.89M+16.8% | $177.56M+16.7% | $170.33M+16.1% | $163.44M+15.5% | |
| Pain management | $94.91M+30.3% | $89.62M+32.8% | $84.82M+37.7% | $79.81M+40.5% | $72.85M+35.9% | |
| Revenue from Contract with Customer, Excluding Assessed Tax by Geography | ||||||
| Europe | $63.37M+20.2% | $61.49M+23.3% | $59.18M+27.0% | $56.23M+29.0% | $52.72M+30.5% | |
| Other International | $7.35M+27.7% | $6.94M+32.5% | $6.69M+44.3% | $6.31M+53.1% | $5.75M+81.1% | |
| Total International | $101.73M+17.8% | $99.16M+20.2% | $95.69M+23.4% | $91.19M+23.7% | $86.36M+25.2% | |
| United States | $450.43M+14.4% | $435.37M+13.7% | $422.62M+14.2% | $408.76M+14.7% | $393.72M+13.9% | |
| Long-Lived Assets by Geography | ||||||
| Europe | $24.23M+36.4% | $23.89M+51.9% | $21.62M+42.8% | $20M+45.0% | $17.77M+37.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AtriCure break its business down?
- AtriCure (ATRC) reports revenue from contract with customer, excluding assessed tax by product across 4 parts — Appendage management, Minimally invasive ablation, Open ablation and Pain management. Each is extracted from the segment footnotes and tracked over time.
- Where does AtriCure's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AtriCure's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
